Last Updated:

Travere Therapeutics

Travere Therapeutics is advancing therapeutic candidates for rare disorders in nephrology, hepatology and metabolism; sponsoring no-cost genetic testing aimed at improving the diagnostic odyssey for children born with cholestasis; partnering with patient advocacy organizations to meet the diverse needs of patients and their families; and ensuring broad access and education for its FDA-approved therapies.

The Company’s pipeline is led by sparsentan, which is being investigated in pivotal Phase 3 clinical trials for rare kidney diseases - focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). The DUPLEX Study in FSGS and the PROTECT Study in IgAN are both positioned for topline readouts from the proteinuria endpoints next year. Travere Therapeutics recently expanded its promising pipeline with the addition of OT-58, now called TVT-058, an investigational human enzyme replacement therapy in Phase 1/2 development for the treatment of classical homocystinuria. Travere Therapeutics continues to partner with leaders in patient advocacy and the National Institutes of Health on early research in rare metabolic and hepatic conditions - NGLY1 deficiency and Alagille syndrome.


Burn Rate (Quarterly)

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

THIOLA® EC (tiopronin)


Quarterly Sales (Approved)

February 12, 2021 (Est)


Focal segmental glomerulosclerosis (FSGS)

Phase 3 (Top-line Data)

Q3 2021


IgA nephropathy (IgAN)

Phase 3 (Top-line Data)

Q3 2021

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon